Cayir, AkinCobanoglu, HayalCoskun, Munevver2025-01-272025-01-2720201742-52551744-7607https://doi.org/10.1080/17425255.2020.1748598https://hdl.handle.net/20.500.12428/24362Background: Eletriptan is a migraine-specific drug-containing the triptan group. In terms of drug safety, the present study aimed to investigate the genotoxic potential of eletriptan. Research design & methods: We conducted our study by using the cytokinesis-block micronucleus cytome (CBMN) assay, a comprehensive method for measuring micronucleus formation, and a sensitive method for detecting DNA-strand breaks. In the assay, cytokinesis-block proliferation index and the frequency of micronuclei were evaluated in lymphocytes treated with three different concentrations (1, 10 and 25 mu g/ml) of eletriptan for 48 hours. In comet assays, DNA damage was evaluated in leucocytes treated with three different concentrations (1, 10 and 25 mu g/ml) of eletriptan for an hour. Results: Eletriptan did not induce cytotoxicity nor any increased micronuclei frequencies. While the comet parameters % DNA in tail, tail moment, and the olive moment was found to be significantly increased at 10 and 25 mu g/ml, the cytokinesis-block proliferation index values were not. Conclusion: These findings suggest that eletriptan is non-cytotoxic but potentially weakly genotoxic at higher concentrations (10 and 25 mu g/ml).eninfo:eu-repo/semantics/closedAccessEletriptangenotoxicitymigrainecomet assaymicronucleusArticle16544144610.1080/17425255.2020.1748598Q1WOS:0005263035000012-s2.0-8508357232932275455Q1